Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EPS (Weighted Average and Diluted) (2023 - 2025)

Immunome's EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.75 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 41.41% year-over-year to -$0.75; the TTM value through Dec 2025 reached -$2.42, up 53.19%, while the annual FY2025 figure was -$2.43, 51.4% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.75 in Q4 2025 per IMNM's latest filing, down from -$0.65 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.35 in Q1 2023 to a low of -$4.22 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$1.08, with a median of -$0.62 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 617.14% in 2024, then surged 79.28% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$4.22 in 2023, then skyrocketed by 69.67% to -$1.28 in 2024, then surged by 41.41% to -$0.75 in 2025.
  • Per Business Quant, the three most recent readings for IMNM's EPS (Weighted Average and Diluted) are -$0.75 (Q4 2025), -$0.65 (Q3 2025), and -$0.5 (Q2 2025).